321 related articles for article (PubMed ID: 32019783)
21. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
[TBL] [Abstract][Full Text] [Related]
22. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
[TBL] [Abstract][Full Text] [Related]
24. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
26. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
28. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Laffel LMB; Tamborlane WV; Yver A; Simons G; Wu J; Nock V; Hobson D; Hughan KS; Kaspers S; Marquard J
Diabet Med; 2018 Aug; 35(8):1096-1104. PubMed ID: 29655290
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
32. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Omar M; Jensen J; Kistorp C; Højlund K; Videbæk L; Tuxen C; Larsen JH; Andersen CF; Gustafsson F; Køber L; Schou M; Møller JE
Cardiovasc Diabetol; 2022 Feb; 21(1):34. PubMed ID: 35219331
[TBL] [Abstract][Full Text] [Related]
33. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA; Angermann CE; Teerlink JR; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Borleffs CJW; Ma C; Comin-Colet J; Fu M; Janssens SP; Kiss RG; Mentz RJ; Sakata Y; Schirmer H; Schou M; Schulze PC; Spinarova L; Volterrani M; Wranicz JK; Zeymer U; Zieroth S; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P
Nat Med; 2022 Mar; 28(3):568-574. PubMed ID: 35228754
[TBL] [Abstract][Full Text] [Related]
34. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
[TBL] [Abstract][Full Text] [Related]
35. Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresis.
Winzeler B; Lengsfeld S; Nigro N; Suter-Widmer I; Schütz P; Arici B; Bally M; Blum C; Bock A; Huber A; Müller B; Christ-Crain M
J Intern Med; 2016 Dec; 280(6):609-617. PubMed ID: 27481546
[TBL] [Abstract][Full Text] [Related]
36. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
[TBL] [Abstract][Full Text] [Related]
37. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
[TBL] [Abstract][Full Text] [Related]
38. Chronic Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis (SIAD) in an Adult Woman with Corpus Callosum Agenesis (CCA).
Silveira MAD; Seguro AC; da Silva JB; Arantes de Oliveira MF; Seabra VF; Reichert BV; Rodrigues CE; Andrade L
Am J Case Rep; 2018 Nov; 19():1345-1349. PubMed ID: 30416193
[TBL] [Abstract][Full Text] [Related]
39. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
40. Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.
Indirli R; Ferreira de Carvalho J; Cremaschi A; Mantovani B; Sala E; Serban AL; Locatelli M; Bertani G; Carosi G; Fiore G; Tariciotti L; Arosio M; Mantovani G; Ferrante E
Front Endocrinol (Lausanne); 2021; 12():689887. PubMed ID: 34108941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
